"Relyvrio: ALS Drug Failure Sparks Market Withdrawal Concerns"

Amylyx Pharmaceuticals' drug Relyvrio, approved for ALS treatment in 2022, has failed to outperform a placebo in a pivotal study, prompting discussions about its removal from the market and raising questions about the FDA's decision to authorize it. The disappointing results have left ALS patients, advocates, and researchers grappling with the next steps in light of the drug's lack of efficacy, highlighting the challenges of regulatory leniency for treatments of devastating, incurable diseases.